Company intelligence / Profile preview
Kinevant Sciences
New York, New York, United Stateskinevant.com ↗
- Ownership
- Private
- Employees
- ~13
- Development stage
- Other
01
Overview
Kinevant's Phase 2 RESOLVE-Lung study for namilumab in chronic active pulmonary sarcoidosis failed to show treatment benefit. The study did not meet its primary endpoint of proportion of subjects with a Rescue Event during the double-blind period. Further development of namilumab for sarcoidosis has been discontinued as of December 2024.[6]
- Therapeutic areas
- PulmonologyImmunology
- Modalities
- Monoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kinevant Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kinevant Sciences.